A Survival Study for Women With Advanced Lung Cancer Who Have Not Previously Received Chemotherapy.
This is a randomized, open-label, multinational, phase III study in women with histologically- or cytologically-confirmed advanced NSCLC who are chemotherapy na√Øve and have PS 2. Study drug will be administered on day 1 of each 21 day cycle
NSCLC
DRUG: paclitaxel|DRUG: paclitaxel poliglumex
The primary objective of this study is to compare the overall survival of female patients randomized to CT-2103 to that of female patients randomized to paclitaxel.
Secondary objectives are to compare the progression-free survival, response rate, disease control, clinical benefit, quality of life, and the safety and tolerability of the treatment arms.
See Summary